Glycogen synthase kinase-3β in ischemic neuronal death

Current Neurovascular Research

Volumn 11, Issue 3, 2014, Pages 271-278

  Hanumanthappa, Pradeep ^a   Densi, Asha ^a   Krishnamurthy, Rajanikant Golgodu ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY CALICUT   (India)

Author keywords

Apoptosis; Brain; GSK 3 ; Hypoxia; Ischemic stroke; Neuronal death

Indexed keywords

BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN P53; ADRENOMEDULLIN; BH3 PROTEIN; BIM PROTEIN; CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; KALLIKREIN; KININ; LIPOPROTEIN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SERINE 9; SERINE DERIVATIVE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; ENZYME ACTIVITY; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL SURVIVAL; DNA BINDING; DNA DAMAGE; DOWN REGULATION; ENERGY RESOURCE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; KALLIKREIN KININ SYSTEM; MITOCHONDRIAL MEMBRANE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; UBIQUITINATION; WNT SIGNALING PATHWAY;

EID: 84906883951     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611666140520151002     Document Type: Article

References (105)

1. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke 1999; 30(10): 2230-7.
2. Ebinger M, Iwanaga T, Prosser JF, et al. Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke. Stroke 2009; 40(7): 2572-4.
3. Albers GW. Advances in intravenous thrombolytic therapy for treatment of acute stroke. Neurology 2001; 57(5): S77-81.
4. Leiva-Salinas C, Wintermark M, Kidwell CS. Neuroimaging of cerebral ischemia and infarction. Neurotherapeutics 2011; 8(1): 19-7.
5. Zhu DY, Deng Q, Yao HH, et al. Inducible nitric oxide synthase expression in the ischemic core and penumbra after transient focal cerebral ischemia in mice. Life Sci 2002; 71(17):1985-96.
6. Furlan M, Marchal G, Viader F, et al. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996; 40(2): 216-26.
7. Sanderson TH, Reynolds CA, Kumar R, et al. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol 2013; 47(1): 9-23.
8. Collino M, Aragno M, Castiglia S, et al. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes 2009; 58(1): 235-42.
9. Miura T, Tanno M. Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther 2010; 24(3): 255-63.
10. Eom TY, Jope RS. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation. Biol Psychiatry 2009; 66(5): 494-502.
11. Zhu LQ, Liu D, Hu J, et al. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J Neurosci 2010; 30(10): 3624-33.
12. Yeste-Velasco M, Folch J, et al. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology 2007; 53(2): 295-307.
13. Mines MA, Beurel E, Jope RS. Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3. Int J Alzheimers Dis 2011; 2011: 861072-83.
14. Dorfman DM, Greisman HA, Shahsafaei A. Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol 2003; 162(5): 1539-44.
15. Cantuti Castelvetri L, Givogri MI, Hebert A, et al. The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3β and deregulation of molecular motors. J Neurosci 2013; 33(24): 10048-56.
16. Miura T, Nishihara M, Miki T. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury. J Pharmacol Sci 2009; 109(2): 162-7.
17. Juhaszova M, Zorov DB, Yaniv Y, et al. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104(11): 1240-52.
18. Xi J, Wang H, Mueller RA, et al. Mechanism for resveratrolinduced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur J Pharmacol 2009; 604(1-3): 111-6.
19. Dolma K, Iacobucci GJ, Hong Zheng K, et al. Presenilin influences glycogen synthase kinase-3β (GSK-3β) for kinesin-1 and dynein function during axonal transport. Hum Mol Genet 2014; 23(5): 1121-33.
20. Bechard M, Trost R, Singh AM, et al. Frat is a phosphatidylinositol 3-kinase/Akt-regulated determinant of glycogen synthase kinase 3βsubcellular localization in pluripotent cells. Mol Cell Biol 2012; 32(2): 288-96.
21. Le Page C, Koumakpayi IH, Alam-Fahmy M, et al. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients Br J Cancer 2006; 94(12): 1906-12.
22. Arcaro A, Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 2007; 8(5): 271-06.
23. Chen X, Zhang Y, Wang Y, et al. PDK1 regulates platelet activation and arterial thrombosis. Blood 2013; 121(18): 3718-26.
24. Lee SL, Chou CC, Chuang HC, et al. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines. PLoS One 2013; 8(6): e67149.
25. Paul I, Bhattacharya S, Chatterjee A, et al. Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk. Genes Cancer 2013; 4(11): 427-46.
26. Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol 2005; 58(3): 225-36.
27. Dajani R, Fraser E, Roe SM, et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J 2003; 22(3): 494-01.
28. Sutherland C. What are the bona fide GSK3 Substrates? Int J Alzheimers Dis 2011; 2011: 505607-31.
29. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009; 8(24): 4032-9.
30. Cole AR. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia. FEBS J 2013; 280(21): 5213-27.
31. Beurel E, Jope RS. The paradoxical pro- and anti-Apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79(4): 173-89.
32. Phukan S, Babu VS, Kannoji A, et al. GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol 2010; 160(1): 1-19.
33. Gall JM, Wong V, Pimental DR, et al. Hexokinase regulates Baxmediated mitochondrial membrane injury following ischemic stress. Kidney Int 2011; 79(11): 1207-16.
34. Peng J, Ramesh G, Sun L, et al. Impaired wound healing in hypoxic renal tubular cells: roles of hypoxia-inducible factor-1 and glycogen synthase kinase 3β/β-catenin signaling. J Pharmacol Exp Ther 2012; 340(1): 176-84.
35. Vasileva AK, Plotnikov EY, Kazachenko AV, et al. Inhibition of GSK-3β decreases the ischemia-induced death of renal cells. Bull Exp Biol Med 2010; 149(3): 303-7.
36. Liu A, Fang H, Dahmen U, et al. Chronic lithium treatment protects against liver ischemia/reperfusion injury in rats. Liver Transpl 2013; 19(7): 762-72.
37. Gao HK, Yin Z, Zhou N, et al. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. J Cardiovasc Pharmacol 2008; 52(3): 286-92.
38. Gao HK, Yin Z, Zhang RQ, et al. GSK-3beta inhibitor modulates TLR2/NF-kappaB signaling following myocardial ischemiareperfusion. Inflamm Res 2009; 58(7): 377-83.
39. Cuzzocrea S, Mazzon E, Esposito E, Muiá C, Abdelrahman M, Di Paola R, et al. Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Med 2007; 33(5): 880-93.
40. Gold AB, Herrmann N, Lanctôt KL. Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke sequelae. Curr Drug Targets 2011; 12(2): 243-55.
41. Liang MH, Chuang DM. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 2007; 282(6): 3904-17.
42. Wang Z, Havasi A, Gall J, et al. GSK3beta promotes apoptosis after renal ischemic injury. J Am Soc Nephrol 2010; 21(2): 284-94.
43. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003; 116(7): 1175-86.
44. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24(9): 441-3.
45. Jacobs KM, Bhave SR, Ferraro DJ, et al. GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol 2012; 2012: 930710.
46. Thotala DK, Hallahan DE, Yazlovitskaya EM. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res 2008; 68(14): 5859-68.
47. Fuller W, Parmar V, Eaton P, et al. Cardiac ischemia causes inhibition of the Na/K ATPase by a labile cytosolic compound whose production is linked to oxidant stress. Cardiovasc Res 2003; 57(4): 1044-51.
48. Lizasoain I, Cárdenas A, Hurtado O, et al. Targets of cytoprotection in acute ischemic stroke: present and future. Cerebrovasc Dis 2006; 21: 1-8.
49. Bhat RV, Shanley J, Correll MP, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA 2000; 97(20): 11074-9.
50. Endo H, Nito C, Kamada H, et al. Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 2006; 26(12): 1479-89.
51. Russell JC, Kishimoto K, O'Driscoll C, et al. Neuronal pentraxin 1 induction in hypoxic-ischemic neuronal death is regulated via a glycogen synthase kinase-3β/β dependent mechanism. Cell Signal 2011; 23(4): 673-82.
52. Al Rahim M, Thatipamula S, Hossain MA. Critical role of neuronal pentraxin 1 in mitochondria-mediated hypoxic-ischemic neuronal injury. Neurobiol Dis 2013; 50: 59-8.
53. Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res 2002; 90(4): 377-9.
54. Wu QL, Shen T, Shao LL, et al. Ischemic postconditioning mediates cardioprotection via PI3K/GSK-3β/β-catenin signaling pathway in ischemic rat myocardium. Shock 2012; 38(2): 165-9.
55. Nishihara M, Miura T, Miki T, et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 2006; 291(2): H748-55.
56. Gomez L, Paillard M, Thibault H, et al. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 2008; 117(21): 2761-8.
57. Gross ER, Hsu AK, Gross GJ. Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am J Physiol Heart Circ Physiol 2008; 294(3): H1497-500.
58. Das S, Wong R, Rajapakse N, et al. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 2008; 103(9): 983-91.
59. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94(7): 960-6.
60. Simão F, Matté A, Pagnussat AS, et al. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Eur J Neurosci 2012; 36(7): 2899-905.
61. Ha T, Hua F, Liu X, et al. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res 2008; 78(3): 546-53.
62. Yin H, Chao L, Chao J. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension 2004; 43(1): 109-16.
63. Clegg HV, Zhang Y. Regulation of the p53 tumor suppressor pathway: the problems and promises of studying Mdm2's E3 ligase function. Crit Rev Eukaryot Gene Expr 2010; 20(1): 77-86.
64. Morrison RS, Kinoshita Y. The role of p53 in neuronal cell death. Cell Death Differ 2000; 7(10): 868-79.
65. Maritsi D, Stagikas D, Charalabopoulos K, et al. What's new in p53? Hippokratia 2006; 10(3): 116-9.
66. Watcharasit P, Bijur GN, Song L, et al. Glycogen synthase kinase- 3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 2003; 278(49): 48872-9.
67. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006; 7(11): 1421-34.
68. Li X, Luo R, Jiang R, et al. The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC Cardiovasc Disord 2013; 13: 8.
69. Stavridi ES, Halazonetis TD. p53 and stress in the ER. Genes Dev 2004; 18(3): 241-4.
70. Zmijewski JW, Jope RS. Nuclear accumulation of glycogen synthase kinase-3 during replicative senescence of human fibroblasts. Aging Cell 2004; 3(5): 309-17.
71. Eom TY, Jope RS. GSK3 beta N-terminus binding to p53 promotes its acetylation. Mol Cancer 2009; 8: 14-24.
72. Leroy K, Boutajangout A, Authelet M, et al. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol 2002; 103(2): 91-9.
73. Shi D, Gu W. Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity. Genes Cancer 2012; 3(3-4): 240-8.
74. Kulikov R, Boehme KA, Blattner C. Glycogen synthase kinase 3- dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 2005; 25(16): 7170-80.
75. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137(4): 609-22.
76. Pei D, Zhang Y, Zheng J. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 2012; 3(3): 228-35.
77. Thotala DK, Hallahan DE, Yazlovitskaya EM. Glycogen synthase kinase 3β inhibitors protect hippocampal neurons from radiationinduced apoptosis by regulating MDM2-p53 pathway. Cell Death Differ 2012; 19(3): 387-96.
78. Luo W, Lin SC. Axin: a master scaffold for multiple signaling pathways. Neurosignals 2004; 13(3): 99-113.
79. Amit S, Hatzubai A, Birman Y, et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002; 16(9): 1066-76.
80. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108(6): 837-47.
81. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17(1): 9-26.
82. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012; 4(5): a008052-65.
83. Kaga S, Zhan L, Altaf E, et al. Glycogen synthase kinase- 3beta/beta-catenin promotes angiogenic and anti-Apoptotic signaling through the induction of VEGF, Bcl-2 and surviving expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol 2006; 40(1): 138-47.
84. L'episcopo F, Tirolo C, Testa N, et al. Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease. Stem Cells 2014 Mar 20. doi: 10.1002/stem.
85. Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007; 12(5): 897-911.
86. Hill MM, Adrain C, Martin SJ. Portrait of a killer: the mitochondrial apoptosome emerges from the shadows. Mol Interv 2003; 3(1): 19-26.
87. Watcharasit P, Thiantanawat A, Satayavivad J. GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption. J Appl Toxicol 2008; 28(4): 466-74.
88. Schinzel A, Kaufmann T, Schuler M, et al. Conformational control of Bax localization and apoptotic activity by Pro168. J Cell Biol 2004; 164(7): 1021-32.
89. Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004; 24(44): 9993-10002.
90. Elyaman W, Terro F, Wong NS, et al. In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation. Eur J Neurosci 2002; 15(4): 651-60.
91. Yamada H, Mizuno S, Reza-Gholizadeh M, et al. Relative importance of NF-kappaB p50 in mycobacterial infection. Infect Immun 2001; 69(11): 7100-5.
92. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001; 107(3): 247-54.
93. Yu Z, Zhou D, Bruce-Keller AJ, et al. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci 1999; 19(20): 8856-65.
94. Kassed CA, Butler TL, Patton GW, et al. Injury-induced NFkappaB activation in the hippocampus: implications for neuronal survival. FASEB J 2004; 18(6): 723-4.
95. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12(8): 695-708.
96. Steinbrecher KA, Wilson W, Cogswell PC, et al. Glycogen synthase kinase 3beta functions to specify gene-specific, NFkappaB- dependent transcription. Mol Cell Biol 2005; 25(19): 8444-55.
97. Wan F, Lenardo MJ. Specification of DNA binding activity of NFkappaB proteins. Cold Spring Harb Perspect Biol 2009; 1(4): a000067.
98. Buss H, Dörrie A, Schmitz ML, et al. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 2004; 279(48): 49571-4.
99. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64(2): 238-58.
100. Numakawa T, Yokomaku D, Richards M, et al. Functional interactions between steroid hormones and neurotrophin BDNF. World J Biol Chem 2010; 1(5): 133-43.
101. Hashimoto R, Takei N, Shimazu K, et al. Lithium induces brainderived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002; 43(7): 1173-9.
102. Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009; 16(3): 649-56.
103. Yasuda S, Liang MH, Marinova Z, et al. The mood stabilizers lithium and valproate selectively activate the promoter IV of brainderived neurotrophic factor in neurons. Mol Psychiatry 2009; 14(1): 51-9.
104. Machado-Vieira R, Manji HK, Zarate CA. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009; 11(2): 92-109.
105. Nguyen TL, Kim CK, Cho JH, et al. Neuroprotection signaling pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19-7/IGF. Exp Mol Med 2010; 42(8): 583-95.